| Literature DB >> 24073005 |
Guangli Yan1, Aihua Zhang, Hui Sun, Weiping Cheng, Xiangcai Meng, Li Liu, Yingzhi Zhang, Ning Xie, Xijun Wang.
Abstract
Acupuncture has a history of over 3000 years and is a traditional Chinese medical therapy that uses hair-thin metal needles to puncture the skin at specific points on the body to promote wellbeing, while its molecular mechanism and ideal biological pathways are still not clear. High-throughput metabolomics is the global assessment of endogenous metabolites within a biologic system and can potentially provide a more accurate snap shot of the actual physiological state. We hypothesize that acupuncture-treated human would produce unique characterization of metabolic phenotypes. In this study, UPLC/ESI-HDMS coupled with pattern recognition methods and system analysis were carried out to investigate the mechanism and metabolite biomarkers for acupuncture treatment at "Zusanli" acupoint (ST-36) as a case study. The top 5 canonical pathways including alpha-linolenic acid metabolism, d-glutamine and d-glutamate metabolism, citrate cycle, alanine, aspartate, and glutamate metabolism, and vitamin B6 metabolism pathways were acutely perturbed, and 53 differential metabolites were identified by chemical profiling and may be useful to clarify the physiological basis and mechanism of ST-36. More importantly, network construction has led to the integration of metabolites associated with the multiple perturbation pathways. Urine metabolic profiling might be a promising method to investigate the molecular mechanism of acupuncture.Entities:
Year: 2013 PMID: 24073005 PMCID: PMC3773888 DOI: 10.1155/2013/429703
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Acupuncture (a) and acupoint map of human meridians (b). c: “Zusanli” acupoint (ST-36).
Figure 2PCA model results for control and model group in positive mode (a). Trajectory analysis of PCA score plots (3D) for the serum samples in positive mode (b). PCA model results for 0 day and 14 days in positive mode (c). VIP plot of OPLS-DA of samples in positive mode (d).
Figure 3PCA model results for control and model group in negative mode (a). Trajectory analysis of PCA score plots (3D) for the serum samples in negative mode (b). PCA model results for 0 day and 14 days in negative mode (c). VIPplot of OPLS-DA of samples in negative mode (d).
Potential biomarkers identified of acupuncture-treated human in positive and negative modes.
| No. | Rt (min) |
|
| Error (mDa) | Ion form | Formula | Metabolite name | VIP value | Trend |
|
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.50 | 162.1126 | 162.1130 | −0.4 | [M + H]+ | C7H15NO3 | Carnitine | 5.1 | ↑ | 0.0087 |
| 2 | 2.32 | 290.1597 | 290.1604 | −0.7 | [M + H]+ | C13H23NO6 | 3-Methylglutarylcarnitine | 4.8 | ↑ | 0.0431 |
| 3 | 3.45 | 276.1815 | 276.1811 | 0.4 | [M + H]+ | C13H25NO5 | Hydroxyhexanoycarnitine | 3.4 | ↑ | 0.0327 |
| 4 | 4.77 | 265.1205 | 265.1188 | 1.7 | [M + H]+ | C13H16N2O4 |
| 9.0 | ↓ | 0.0010 |
| 5 | 4.86 | 316.1761 | 316.1760 | 0.1 | [M + H]+ | C15H25NO6 | Derivative of carnitine | 3.8 | ↑ | 0.0426 |
| 6 | 5.48 | 300.1818 | 300.1811 | 0.7 | [M + H]+ | C15H25NO5 | Derivative of carnitine | 4.6 | ↑ | 0.0000 |
| 7 | 5.55 | 318.1922 | 318.1917 | 0.5 | [M + H]+ | C15H27NO6 | Derivative of carnitine | 7.2 | ↑ | 0.0366 |
| 8 | 5.71 | 135.0433 | 135.0446 | −1.1 | [M + H]+ | C8H6O2 | 6Z-Octene-2,4-diynoic acid | 8.1 | ↓ | 0.0230 |
| 9 | 5.98 | 225.1089 | 225.1103 | −1.4 | [M + Na]+ | C10H18O4 | Sebacic acid | 2.0 | ↓ | 0.0000 |
| 10 | 6.29 | 302.1969 | 302.1981 | −1.2 | [M + H]+ | C15H27NO5 | Derivative of carnitine | 5.7 | ↑ | 0.0039 |
| 11 | 7.17 | 284.1844 | 284.1862 | −1.8 | [M + H]+ | C15H25NO4 | Supinine | 6.9 | ↑ | 0.0039 |
| 12 | 7.65 | 161.0599 | 161.0603 | −0.4 | [M + H]+ | C10H8O2 | 1-Formyl-2-indanone | 3.0 | ↓ | 0.0263 |
| 13 | 7.68 | 354.2273 | 354.2280 | −0.7 | [M + H]+ | C19H31NO5 | Derivative of carnitine | 3.5 | ↑ | 0.0015 |
| 14 | 7.71 | 233.1166 | 233.1154 | 1.2 | [M + Na]+ | C12H18O3 | Jasmonic acid | 2.9 | ↑ | 0.0083 |
| 15 | 8.00 | 137.0607 | 137.0603 | 0.4 | [M + H]+ | C8H8O2 | 3-Vinylcatechol | 6.6 | ↑ | 0.0019 |
| 16 | 8.08 | 330.2264 | 330.2280 | −4.8 | [M + H]+ | C17H31NO5 | 6-Keto-decanoylcarnitine | 11.8 | ↓ | 0.0048 |
| 17 | 8.17 | 286.2018 | 286.2018 | 0.0 | [M + H]+ | C15H27NO4 | 2-Octenoylcarnitine | 26.1 | ↑ | 0.0000 |
| 18 | 8.31 | 332.2440 | 332.2437 | 0.3 | [M + H]+ | C17H33NO5 | Derivative of carnitine | 3.9 | ↑ | 0.0000 |
| 19 | 8.32 | 330.2272 | 330.2280 | −0.8 | [M + H]+ | C17H31NO5 | 6-Keto-decanoylcarnitine | 5.7 | ↓ | 0.0077 |
| 20 | 10.11 | 356.2424 | 356.2437 | −1.3 | [M + H]+ | C19H33NO5 | Derivative of carnitine | 2.3 | ↓ | 0.0024 |
| 21 | 10.50 | 288.2167 | 288.2175 | −0.8 | [M + H]+ | C15H29NO4 | L-Octanoylcarnitine | 3.9 | ↑ | 0.0027 |
| 22 | 10.72 | 358.2587 | 358.2593 | −0.6 | [M + H]+ | C19H35NO5 | Derivative of carnitine | 3.7 | ↓ | 0.0000 |
| 23 | 12.54 | 312.2162 | 312.2175 | −1.3 | [M + H]+ | C17H29NO4 | 2-trans,4-cis-Decadienoylcarnitine | 9.5 | ↓ | 0.0000 |
| 24 | 12.62 | 314.2345 | 314.2331 | 1.4 | [M + H]+ | C17H31NO4 | 9-Decenoylcarnitine | 3.1 | ↓ | 0.0242 |
| 25 | 12.79 | 312.2169 | 312.2175 | −0.6 | [M + H]+ | C17H29NO4 | 2-trans,4-cis-Decadienoylcarnitine | 10.7 | ↓ | 0.0010 |
| 26 | 13.98 | 338.2312 | 338.2307 | 0.5 | [M + Na]+ | C17H33NO4 | L-Decanoylcarnitine | 7.7 | ↓ | 0.0001 |
| 27 | 14.25 | 338.2310 | 338.2307 | 0.3 | [M + Na]+ | C17H33NO4 | L-Hexanoylcarnitine | 7.6 | ↑ | 0.0000 |
| 28 | 14.49 | 338.2321 | 338.2307 | 1.4 | [M + Na]+ | C17H33NO4 | L-Decanoylcarnitine | 7.5 | ↓ | 0.0023 |
| 29 | 15.93 | 489.2449 | 489.2464 | −1.5 | [M + Na]+ | C25H38O8 | Androsterone glucuronide | 2.5 | ↓ | 0.0171 |
| 30 | 17.02 | 279.2342 | 279.2324 | 1.8 | [M + H]+ | C18H30O2 |
| 2.5 | ↓ | 0.0019 |
| 31 | 0.65 | 191.0183 | 191.0192 | −0.9 | [M − H]− | C6H8O7 | Citric acid | 14.9 | ↑ | 0.0005 |
| 32 | 0.76 | 129.0177 | 129.0188 | −1.1 | [M − H]− | C5H6O4 | Mesaconic acid | 8.3 | ↑ | 0.0000 |
| 33 | 0.86 | 199.0080 | 199.0099 | −1.9 | [M − H]− | C5H12O4S2 | 2-Hydroxypropyl-CoM | 3.5 | ↓ | 0.0000 |
| 34 | 0.99 | 232.0275 | 232.0280 | −0.5 | [M − H]− | C8H11NO5S | Dopamine 3-O-sulfate | 2.3 | ↓ | 0.0005 |
| 35 | 1.03 | 161.0444 | 161.0450 | −0.6 | [M − H]− | C6H10O5 | 3-Hydroxy-3-methyl-glutaric acid | 3.1 | ↑ | 0.0000 |
| 36 | 1.11 | 182.0461 | 182.0453 | 0.8 | [M − H]− | C8H9NO4 | 4-Pyridoxic acid | 2.2 | ↑ | 0.0000 |
| 37 | 1.43 | 253.0827 | 253.0824 | 0.3 | [M − H]− | C11H14N2O5 | Nicotinamide riboside | 3.2 | ↓ | 0.0029 |
| 38 | 2.42 | 225.0860 | 225.0875 | −1.5 | [M − H]− | C10H14N2O4 | Porphobilinogen | 3.1 | ↓ | 0.0000 |
| 39 | 3.49 | 212.0002 | 212.0018 | −1.6 | [M − H]− | C8H7NO4S | Indoxyl sulfuric acid | 6.0 | ↓ | 0.0000 |
| 40 | 4.68 | 263.0994 | 263.1032 | −3.8 | [M − H]− | C13H16N2O4 |
| 3.7 | ↓ | 0.0007 |
| 41 | 5.70 | 187.0048 | 187.0065 | −1.7 | [M − H]− | C7H8O4S | 4-Sulfobenzyl alcohol | 4.7 | ↓ | 0.0144 |
| 42 | 5.79 | 193.0353 | 193.0348 | 0.5 | [M − H]− | C6H10O7 | Unknown | 3.2 | ↑ | 0.0001 |
| 43 | 6.21 | 377.1456 | 377.1461 | −0.5 | [M − H]− | C17H22N4O6 | Reduced riboflavin | 6.5 | ↓ | 0.0001 |
| 44 | 6.39 | 201.1112 | 201.1127 | −1.5 | [M − H]− | C10H18O4 | Sebacic acid | 4.5 | ↓ | 0.0000 |
| 45 | 6.55 | 173.0799 | 173.0814 | −1.5 | [M − H]− | C8H14O4 | Suberic acid | 2.8 | ↓ | 0.0002 |
| 46 | 7.53 | 229.1425 | 229.1440 | −1.5 | [M − H]− | C12H22O4 | Dodecanedioic acid | 3.9 | ↓ | 0.0000 |
| 47 | 7.68 | 153.0905 | 153.0916 | −1.1 | [M − H]− | C9H14O2 | 5,7-Nonadienoic acid | 3.0 | ↑ | 0.0000 |
| 48 | 7.77 | 225.1595 | 225.1603 | −0.8 | [M − H]− | C12H22N2O2 | 1,8-Diazacyclotetradecane-2,9-dione | 2.1 | ↓ | 0.0000 |
| 49 | 7.78 | 145.0593 | 145.0613 | −2.0 | [M − H]− | C5H10N2O3 | L-Glutamine | 7.2 | ↓ | 0.0015 |
| 50 | 7.96 | 185.1181 | 185.1178 | 0.3 | [M − H]− | C10H18O3 | 10-oxo-decanoic acid | 3.2 | ↓ | 0.0000 |
| 51 | 8.06 | 141.0901 | 141.0916 | −1.5 | [M − H]− | C8H14O2 | Unknown | 4.8 | ↑ | 0.0000 |
| 52 | 8.20 | 199.0956 | 199.0970 | −1.4 | [M − H]− | C10H16O4 | Decenedioic acid | 4.9 | ↑ | 0.0016 |
| 53 | 9.09 | 179.1069 | 179.1072 | −0.3 | [M − H]− | C11H16O2 | 3-tert-Butyl-5-methylcatechol | 3.5 | ↑ | 0.0009 |
Figure 4Mass fragment information of alpha-N-phenylacetyl-L-glutamine in negative mode (a) and 9-decenoylcarnitine in positive mode (b).
Figure 5Construction of the arachidonic acid metabolism pathways in acupuncture-treated human. The map was generated using the reference map by KEGG (http://www.genome.jp/kegg/). The green boxes: enzymatic activities with putative cases of analogy in acupuncture-treated human. 1: alpha-linolenic acid metabolism; 2: D-glutamine and D-glutamate metabolism; 3: citrate cycle (TCA cycle); 4: alanine, aspartate, and glutamate metabolism; 5: vitamin B6 metabolism.